

November 24, 2014



Amarantus to Present at the LD Micro Main Event VII Investor Conference on December 2, 2014

- Live Webcast of Presentation on Tuesday, December 2, 2014 at 10:30 a.m. PST / 1:30 p.m. EST -

SAN FRANCISCO and GENEVA, Nov. 24, 2014 (GLOBE NEWSWIRE) --[Amarantus Bioscience Holdings, Inc.](#) (OTCQB:AMBS), a diversified biotechnology company focused on the development of diagnostic and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine announced today that Gerald E. Commissiong, President and Chief Executive Officer, will present at the [LD Micro Main Event VII](#) micro-cap investor conference being held December 2 - 4, 2014 at the Luxe Sunset Hotel in Los Angeles, California.

Mr. Commissiong will present on Tuesday, December 2, 2014 at 10:30 a.m. PST (1:30 p.m. EST) and will provide an update on Amarantus' recent corporate milestone achievements, clinical development progress and expected near-term catalysts.

A live audio webcast of the presentation may be accessed via the News and Events page of the Investor Relations section of the Amarantus corporate web site under the [IR Calendar](#) at www.amarantus.com. A replay of the webcast will be available approximately two hours after the presentation ends and will be archived for 30 days.

Investors attending the conference may schedule one-on-one meetings with Mr. Commissiong in advance or onsite directly through LD Micro.

About LD Micro

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational. LD Micro is a non-registered investment advisor. For more information, please contact (408) 457-1042 or visit www.ldmicro.com.

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's disease Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro

Test[®]) for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). In November 2014, AMBS entered into an exclusive option agreement with Lonza Walkersville, Inc., a subsidiary of Lonza Group Ltd., to acquire Cutanogen Corporation, a subsidiary of Lonza Walkersville, to develop Engineered Skin Substitute (ESS-W), an autologous skin replacement product for the treatment of Stage 3 and Stage 4 intractable severe burns. For further information please visit www.Amarantus.com, or connect with the Company on [Facebook](#), [LinkedIn](#), [Twitter](#) and [Google+](#).

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

CONTACT: Investor Contact:

Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T: (US) 908.938.1475
E: jenene@jenenethomascommunications.com

Shareholder Contact:

Aimee Boucher, Investor Relations
T: (US) 408.737.2734 x 101
E: ir@amarantus.com

Media Contact:

Planet Communications
Deanne Eagle, Media Contact
T: (US) 917.837.5866

Source: Amarantus BioScience Holdings, Inc.